Amgen (AMGN) Cash & Equivalents (2009 - 2026)

Amgen's Cash & Equivalents history runs 18 years deep, the most recent figure standing at $12.0 billion for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 36.64% year-over-year to $12.0 billion; the TTM figure through Mar 2026 stood at $12.0 billion (up 36.64% YoY), while the FY2025 annual figure was $9.1 billion, down 23.75% from the prior year.
• Cash & Equivalents was $12.0 billion for Q1 2026 at Amgen, up from $9.1 billion in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $34.7 billion in Q3 2023 to a low of $5.2 billion in Q2 2022.
• Historically, Cash & Equivalents has averaged $13.4 billion across 5 years, with a median of $9.4 billion in 2025.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents soared 558.24% in 2023, then tumbled 74.06% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $7.6 billion in 2022, then soared by 43.45% to $10.9 billion in 2023, then climbed by 9.4% to $12.0 billion in 2024, then dropped by 23.75% to $9.1 billion in 2025, then soared by 31.87% to $12.0 billion in 2026.
• The last three Cash & Equivalents figures came in at $12.0 billion (Q1 2026), $9.1 billion (Q4 2025), and $9.4 billion (Q3 2025), per Business Quant data.